Hemispherx’s Ampligen Poised To Become First Approval For Chronic Fatigue Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA staff scheduling changes are behind a 1-2 week delay of action on May 25 user fee goal.